Showing results (91-100 of 174) with videos related to
Sort By:
Pageof 18
JAMA|October 11, 2012
Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortalityOlle Melander, Alan S Maisel, Peter Almgren, et al.Epigenetics|May 6, 2016
DNA methylation of loci within ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes riskTasnim Dayeh, Tiinamaija Tuomi, Peter Almgren, et al.Plos One|August 23, 2013
Plasma lipid composition and risk of developing cardiovascular diseaseCeline Fernandez, Marianne Sandin, Julio L Sampaio, et al.Prostaglandins & Other Lipid Mediators|May 20, 2015
Intakes of omega-3 polyunsaturated fatty acids and blood pressure change over time: Possible interaction with genes involved in 20-HETE and EETs metabolismAngela Tagetti, Ulrika Ericson, Martina Montagnana, et al.The Journal of Clinical Investigation|October 20, 2007
Genetic and epigenetic factors are associated with expression of respiratory chain component NDUFB6 in human skeletal muscleCharlotte Ling, Pernille Poulsen, Stina Simonsson, et al.Diabetologia|September 8, 2016
Interaction between the obesity-risk gene FTO and the dopamine D2 receptor gene ANKK1/TaqIA on insulin sensitivityMartin Heni, Stephanie Kullmann, Emma Ahlqvist, et al.Diabetes|December 24, 2004
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetesValeriya Lyssenko, Peter Almgren, Dragi Anevski, et al.Journal of the American College of Cardiology|November 13, 2010
Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillationJ Gustav Smith, Christopher Newton-Cheh, Peter Almgren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer RiskOlle Melander, Marju Orho-Melander, Jonas Manjer, et al.Journal of Addiction Medicine|April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical TrialMichelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.Pageof 18